沃森生物: 关于公司及子公司向银行申请授信额度的公告

Core Viewpoint - Yunnan Watson Bio-Tech Co., Ltd. plans to apply for credit limits from several banks to support its business development and daily operational needs, aiming to expand financing channels and reduce funding costs [1][2]. Summary by Sections Credit Limit Application Overview - The company and its subsidiaries, Yuxi Watson Bio-Tech Co., Ltd. and Yuxi Zerun Bio-Tech Co., Ltd., intend to apply for credit limits from China Construction Bank, China Merchants Bank, Agricultural Bank of China, China Everbright Bank, Yunnan Hongta Bank, Citic Bank, and Industrial Bank [1]. - The credit will be used for research and development, production, sales, and daily operational expenses [1][2]. - The proposed credit limits and terms are detailed in a table, indicating that the credit will be unsecured and based on the company's creditworthiness [1][2]. Board of Directors' Opinion - The board agrees with the subsidiaries' need for credit to support their operational requirements, emphasizing that the credit will be used for normal business activities and will not harm the interests of shareholders, especially minority shareholders [2]. Supervisory Board's Opinion - The supervisory board supports the credit application, stating that the funds will facilitate production and operational efficiency, aligning with the company's normal funding needs [2].